The NWO-funded UNRANU consortium brings together researchers, clinicians, companies, and patient organizations with one common goal: to better understand and improve the radiobiological effects of radionuclide therapy in cancer. We do this, for example, by comparing the effects of different types of radiation. In addition, we aim to improve the availability of radionuclides for the radiopharmaceutical industry and hospitals, and ultimately for patients. To achieve this, we develop methods that enhance the production of radionuclides. The knowledge gained on radiobiology and production methods should ultimately lead to more personalized treatments, in which tumors are treated more effectively and side effects are reduced by using the most optimal radionuclide. Apart from the UNRANU project, the associated researchers are exploring further collaboration possibilities to advance radiobiological insights.

2024-2028
Dr. Frank Nijsen, Prof. Sandra Heskamp, Radboudumc, Dr. Julie Nonnekens, Erasmus MC, Prof. Antonia Denkova, TU Delft
Radboudumc, Erasmus MC, TUDelft, Reinier de Graaf Gasthuis, Meander Medisch Centrum, NVL, NVNG, Oncode, Stichting Darmkanker, VSL, TerThera, Radboud Translational Medicine, MILabs, HUB Organoids, Alfarim, NRG PALLAS, Siemens Healthineers, Urenco Nederland B.V., Von Gahlen
Website: https://unranu.nl/